Refractive Error Change and Overminus Lens Therapy for Childhood Intermittent Exotropia
Writing Committee for the Pediatric Eye Disease Investigator Group,Pediatric Eye Disease Investigator Group,Angela M Chen,S Ayse Erzurum,Danielle L Chandler,Amra Hercinovic,Rui Wu,Marilyn Vricella,Amy L Waters,Benjamin H Ticho,John W Erickson,Silvia Han,Paula S McDowell,Zhuokai Li,Raymond T Kraker,Jonathan M Holmes,Susan A Cotter,Monsey L Alexander,Megan Allen,Sreevardhan Alluri,Deborah M Amster,Heather A Anderson,Afifa Argoubi,William F Astle,Darrell S Austin,Maragaret K Bailey,John D Baker,Wesley T Beaulieu,Roy W Beck,Fabiana Berns,Amit R Bhatt,Eileen E Birch,Derek P Bitner,Tracy A Bland,Marie I Bodack,Charline S Boente,Lisa Bohra,Lezlie L Bond,Erick D Bothun,Nicole M Boyle,Randy C Brafford,Kelly M Castle,Carolyn Chamberlain,Nathan L Cheung,Stephen P Christiansen,Alex Christoff,Ida Chung,Katherine R Cioffi,Deborah A Clausius,Patricia Cobb,Mary Louise Z Collins,Beth J Colon,Julie A Conley,Courtney L Conner,Katie S Connolly,Karen Cooper,Connie J Crossnoe,Eric R Crouch,Shawn L Cupit,Linda T Curtis,Beth M Cutrer,Barry Davis,Alejandra G de Alba Campomanes,Erika A De Leon,Trevano W Dean,Marie I Diener-West,Angela C Dillon,Zainab Dinani,Quayleen Donahue,Sean P Donahue,Patrick J Droste,Zuzana Ecerova,Jillian M Eltzroth,Christina A Esposito,Patricia L Evans,Donald F Everett,Caroline C Fang,Alicia E Feis,Lisa M Fergus,Brooke P Fimbel,Deborah R Fishman,Maureen A Flanagan,Roberta A Forde,Samisksha Fouzdar Jain,John Mark Franklin,Marcela Frazier,Jennifer B Gafford,Brooke E Geddie,Kevin R Gertsch,Elena Gianfermi,Michael E Gray,Adriana P Grigorian,Kammi B Gunton,Alexis C Hahn,Laurie Hahn-Parrott,Kathryn M Haider,Wendy Jean Haley,Stanley W Hatch,Sarah R Hatt,Robert J Henderson,Catherine L Heyman,Rosemary D Higgins,Jan Hilbrands,James E Hoepner,Ann M Holleschau,Hannah L Holtorf,Darren L Hoover,Kristine B Hopkins,Kristine Huang,Amy K Hutchinson,Yvonne R James,Benjamin G Jastrzemsbki,Erin C Jenewein,Allison A Jensen,Jasleen K Jhajj,Sarah K Jones,Catherine O Jordan,Joseph D Kaplon,Shabana Khan,Lindsay D Klaehn,Lingkun Kong,Emily R Koontz,Cassandra A Koutnik,Andrea M Kramer,Courtney L Kraus,Samantha L Krueger,Marjean T Kulp,Sudhi P Kurup,Kara C LaMattina,Jennifer E Lambert,Scott R Lambert,Cristina L Law,Elizabeth L Lazar,Shelby Leach,Katherine A Lee,David A Leske,Maria E Lim,Xiaonong Liu,Ingryd Lorenzana,Rachel N Loud,Don W Lyon,Alex F Lyons,Sonia Manuchian,Lauren Marozas,Justin D Marsh,Stacy R Martinson,Laura M May,Laura McCoy Vrablec,J Ryan McMurtrey,Gail C Meil,B Michele Melia,Kim S Merrill,Rebecca B Mets-Halgrimson,Sara R Meyers,Aaron M Miller,Caiytlin C Miller,Brian G Mohney,Jenifer Montejo,Linda Morgan,Kelsie B Morrison,Ann M Morrison,David G Morrison,Jenny Myung,David L Nash,Elyse Nylin,Tamara S Oechslin,Maria N Olvera,Gillaine Ortiz,Teresa Oseguera,Yi Pang,Sue M Parker,Reena A Patel,Evelyn A Paysse,Jason H Peragallo,Susan N Perzyk,Robert J Peters,Paul H Phillips,Maureen D Plaumann,Larry W Plum,Stephen W Poff,Karen E Pollack,Jennifer N Qayum,Micaela N Quebbemann,Aparna Raghuram,Bahram Rahmani,Hantamalala Ralay Ranaivo,Michael X Repka,Dashaini V Retnasothie,Tawna L Roberts,Julianne L Robinson,Matthew K Roe,Gihan Romany,Daniella Rutner,Allyson Sala,Emi N Sanders,Richard A Saunders,Amar Sayani,Mitchell M Scheiman,Erica L Schulman-Ellis,Birva K Shah,Veeral S Shah,Erica R Shelton,R Michael Siatkowski,Kristin E Slinger,Rachel M Smith,Casandra S Solis,Magdalena Stec,Nancy E Stevens,Julia L Stevens,Miqua L Stewart,Sasha Strul,Kathleen M Stutz,Donny W Suh,Allison I Summers,Roseanne Superstein,Desirae R Sutherland,Susanna M Tamkins,Marc B Taub,Maryse Thibeault,Jenna R Titelbaum,Tiffany T Tolbert,Andrew J Toole,David O Toro,Irene T Tung,Christina M Twardowski,Lawrence Tychsen,Vivian Tzanetakos,Kelly D Varney,Gaylord G Ventura,Lisa C Verderber,Kimberly R Walker,Palak B Wall,David K Wallace,Jingyun Wang,Katherine K Weise,Suzanne M Wernimont,Christi M Willen,Elisabeth T Wolinski,Victoria C Woodard,Martha M Wright,Tomohiko Yamada,Kimberly G Yen,Amanda M Yonkers,Sharon F Freedman,Melanie L Christian,Earl R Crouch Jr,Laura B Enyedi,William V Good,Jorie L Jackson,Richard London,Vivian M Manh,Ruth E Manny,Beth A Morrell,David B Petersen,Stacy L Pineles,David L Rogers,Scott T Ruark,Bonita R Schweinler,Jayne L Silver
DOI: https://doi.org/10.1001/jamaophthalmol.2024.0276
2024-05-01
Abstract:Importance: Increased myopic shift was found to be associated with 1 year of overminus spectacle treatment for children with intermittent exotropia (IXT). Persistence of myopic shift after discontinuing overminus spectacles is unknown. Objective: To compare refractive error change over 3 years in children with IXT originally treated with overminus vs nonoverminus spectacles. Design, setting, and participants: This study was an 18-month extension of the Trial of Overminus Spectacle Therapy for Intermittent Exotropia cohort, which previously randomized children aged 3 to 10 years with IXT and baseline spherical equivalent refractive error (SER) between -6.00 diopters (D) and 1.00 D to overminus spectacles (-2.50 D for 12 months, -1.25 D for 3 months, and nonoverminus for 3 months) or nonoverminus spectacles. Children were recruited from 56 sites from July 2010 to February 2022. Data were analyzed from February 2022 to January 2024. Interventions: After trial completion at 18 months, participants were followed up at 24 and 36 months. Treatment was at investigator discretion from 18 to 36 months. Main outcomes and measures: Change in SER (cycloplegic retinoscopy) from baseline to 36 months. Results: Of 386 children in the Trial of Overminus Spectacle Therapy for Intermittent Exotropia, 223 (57.8%) consented to 18 months of additional follow-up, including 124 of 196 (63.3%) in the overminus treatment group and 99 of 190 (52.1%) in the nonoverminus treatment group. Of 205 children who completed 36-month follow-up, 116 (56.6%) were female, and the mean (SD) age at randomization was 6.2 (2.1) years. Mean (SD) SER change from baseline to 36 months was greater in the overminus group (-0.74 [1.00] D) compared with the nonoverminus group (-0.44 [0.85] D; adjusted difference, -0.36 D; 95% CI, -0.59 to -0.12; P = .003), with 30 of 112 (26.8%) in the overminus group having more than 1 D of myopic shift compared with 14 of 91 (15%) in the nonoverminus group (risk ratio, 1.8; 95% CI, 1.0-3.0). From 12 to 36 months, mean (SD) myopic shift was -0.34 (0.67) D and -0.36 (0.66) D in the overminus and nonoverminus groups, respectively (adjusted difference, -0.001 D; 95% CI, -0.18 to 0.18; P = .99). Conclusions and relevance: The greater myopic shift observed after 1 year of -2.50-D overminus lens treatment remained at 3 years. Both groups had similar myopic shift during the 2-year period after treatment weaning and cessation. The risk of myopic shift should be discussed with parents when considering overminus lens treatment. Trial registration: ClinicalTrials.gov Identifier: NCT02807350.